TG Therapeutics, Inc.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| NKB2.F | B9A.F | ROIV | VERA | GMAB | 9969.HK | |
|---|---|---|---|---|---|---|
| Market cap | 8.30B | 2.45B | 27.61B | 2.30B | 33.89B | 21.56B |
| P/E (TTM) | 23.0 | 250.7 | — | — | 43.4 | 20.3 |
| Forward P/E | -23.7 | — | -27.5 | -7.5 | 34.9 | 53.2 |
| Price/book | 14.3 | 1.2 | 6.5 | 5.6 | 5.5 | 1.9 |
| Dividend yield | — | 0.68% | — | — | — | — |
| 1-year change | +83.45% | +13.08% | +85.85% | +27.43% | +91.12% | −14.61% |
| Today | −2.52% | −0.29% | +6.08% | +4.10% | −0.72% | +1.33% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 15 min.
Latest news
All NKB2.F news ›TG Therapeutics to Host Conference Call on Third Quarter 2026 Financial Results and Business Update
BioSpace TG Therapeutics to Host Conference Call on Third Quarter 2026 Financial Results and Business Update CONFERENCE CALL TO BE HELD MONDAY, NOVEMBER 9, 2026, AT 8:30 AM ET NEW YORK--(BUSINESS WI
TG Therapeutics: The Business Is More Attractive Than The Valuation
TG Therapeutics delivered strong BRIUMVI sales growth, raising 2024 revenue guidance and approaching blockbuster status. Learn why TGTX stock is a hold. - TG Therapeutics delivered strong BRIUMVI sales growth, raising 2024 revenue guidance…
Analysts’ Opinions Are Mixed on These Healthcare Stocks: TG Therapeutics (TGTX) and Insulet (PODD)
Analysts have been eager to weigh in on the Healthcare sector with new ratings on TG Therapeutics (TGTX) and Insulet (PODD). In a report released today, Tara Bancroft from TD Cowen maintained a Buy rating on TG Therapeutics, with a price…
TG Therapeutics Announces Schedule of Data Presentations at MSToronto2026
TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the schedule of upcoming presentations at the 10th Joint ACTRIMS-ECTRIMS Meeting, also referred to as MSToronto2026, being held October 21-23, ... - Download the Globe app to my phone…
TG Therapeutics (TGTX) Expected to Post Earnings on Monday
Check Out Our Latest Stock Analysis on TG Therapeutics TG Therapeutics, Inc is a commercial-stage biopharmaceutical company focused on developing and delivering medicines for B-cell diseases, including multiple sclerosis and certain blood…
TG Therapeutics Announces Phase 1 Data Evaluating Azer-cel in Progressive Multiple Sclerosis in a Late-Breaking Oral Presentation at MSToronto2026
Weiss, Chairman and Chief Executive Officer of TG Therapeutics, stated, “These initial azer-cel results are particularly encouraging given that all patients entered the study with progressive ... - Download the Globe app to my phone or…
TG Therapeutics Highlights New Clinical Data Across Multiple Sclerosis Portfolio at MSToronto2026
Seven-year BRIUMVI data demonstrate sustained disease control, with approximately 88% of participants remaining free from confirmed disability progression after 7 years of continuous treatment Phase 1 subcutaneous BRIUMVI bioavailability…
TG Therapeutics reports seven-year BRIUMVI disability and safety findings
Confirmed disability progression affected 11.7 per cent with continuous treatment versus 17.4 per cent after an initial comparator. Confirmed disability progression affected 11.7 per cent of continuously treated BRIUMVI patients over seven…
TG Therapeutics Announces Publication of Five-Year Comparative Analysis of BRIUMVI Versus Ocrelizumab and Ofatumumab in Relapsing Multiple Sclerosis
BRIUMVI was associated with a lower risk of 24-week confirmed disability progression and lower annualized relapse rates (ARRs) over five years compared with ocrelizumab and ofatumumab The manuscript can be accessed at ScienceDirect.com or…
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Most coverage from
- biospace.com1
- defenseworld.net1
- financialcontent.com1
- joplinglobe.com1
- seekingalpha.com1
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 6 articles, not a forecast.